Exact(12)
In this multicenter, community-based phase II trial, we evaluated carboplatin and weekly topotecan in the previously untreated patients with extensive stage SCLC.
Methods: From 2003 to 2015, patients with advanced lung cancer including non-small cell lung cancer (NSCLC) with stage IIIB or IV and small cell lung cancer (SCLC) with extensive stage who admitted to ICU were included and reviewed.
Thus, the treatment and prognosis of a patient with extensive stage SCLC is markedly different than for a patient with synchronous limited stage SCLC and stage IA NSCLC.
Although the proportions of patients with extensive stage disease and with PS2 were similar in both studies, the choice and doses of drugs are not directly comparable.
DC samples were obtained from biopsies taken from eight DC patients with extensive, stage 2 or 4 fibrosis of the palmar fascia during open radical palmar fasciectomy.
Two Japanese groups observed improved survival in patients with extensive stage (ES) SCLC when cisplatin was combined with irinotecan (Noda et al, 2002; Han et al, 2005).
Similar(48)
Phase II evaluation of the regimen in patients with extensive-stage SCLC is ongoing.
The prognosis for patients with extensive-stage small-cell lung cancer remains poor.
CONCLUSION: Our preliminary conclusion is that the sequential and alternating regimens resulted in comparable activity and tolerability in previously untreated patients with extensive-stage SCLC.
A phase 1b-2 trial of obatoclax administered using two infusion regimens in combination with carboplatin and etoposide has been completed in previously untreated patients with extensive-stage SCLC.
This phase I/IIA study evaluated the maximum-tolerated dose (MTD), safety, and clinical benefit of pomalidomide, an immunomodulatory drug (IMiD), combined with cisplatin+etoposide chemotherapy, in treatment-naive patients with extensive-stage (ES) small-cell lung cancer (SCLC).
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com